

Please substitute the following claim 27 for the pending claim 27:

β^3 27.^b (Once amended) The method of claim 26,^c wherein the chelator is bathocuproine.

Please substitute the following claim 42 for the pending claim 42:

β^4 42.^a (Once amended) The pharmaceutical composition of claim 41,^d wherein the chelator specific for the reduced form of copper is bathocuproine.

Please add the following new claims:

β^5 58.¹⁰ (New) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a hydrophobic derivative of a chelator specific for the reduced form of copper, and (b) clioquinol; wherein said combination reduces, inhibits or otherwise interferes with A β -mediated production of radical oxygen species.

59.¹¹ (New) The method of claim 58 wherein said chelator specific for the reduced form of copper is bathocuproine.

60.¹² (New) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a hydrophobic derivative of a chelator specific for the reduced form of copper, and (b)

clioquinol; wherein said combination prevents formation of A β amyloid, promotes, induces or otherwise facilitates resolubilization of A β deposits, or both.

¹³

¹²

61. (New) The method of claim 60 wherein said chelator specific for the reduced form of copper is bathocuproine.

¹⁴

62. (New)

A pharmaceutical composition for treatment of conditions caused by amyloidosis, A β -mediated ROS formation, or both, comprising a hydrophobic derivative of a chelator specific for the reduced form of copper, with one or more pharmaceutically acceptable carriers or diluents.

¹⁵

¹⁴

63. (New)

The pharmaceutical composition of claim 62 wherein said chelator specific for the reduced form of copper is a bathocuproine.

β 5 cont